Biological markers in schizophrenia: An update

Drugs of Today

Volumn 46, Issue 9, 2010, Pages 661-669

  Madaan, Vishal ^a   Bestha, Durga Prasad ^a   Kolli, Venkata Bharadwaj ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; DYSBINDIN; GLUTAMIC ACID; INTERLEUKIN 2; INTERLEUKIN 6; N ACETYLASPARTIC ACID; NEU DIFFERENTIATION FACTOR; PHOSPHODIESTERASE; PROLINE DEHYDROGENASE; PROTEIN P300; PROTEIN P50; RGS4 PROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

AMYGDALOID NUCLEUS; ARCUATE FASCICULUS; ATTENTION; BRAIN SIZE; CINGULATE GYRUS; COMPUTER ASSISTED TOMOGRAPHY; CORPUS CALLOSUM; DEPTH PERCEPTION; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; EPIGENETICS; EVOKED RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC MARKER; HIPPOCAMPUS; HUMAN; LANGUAGE ABILITY; LATERAL GENICULATE BODY; MISMATCH NEGATIVITY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAHIPPOCAMPAL GYRUS; PNEUMOENCEPHALOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREPULSE INHIBITION; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL ADAPTATION; SUPERIOR TEMPORAL GYRUS; THALAMUS DORSOMEDIAL NUCLEUS; UNCINATE FASCICULUS; VELOCARDIOFACIAL SYNDROME; VERBAL MEMORY; WORKING MEMORY;

BIOLOGICAL MARKERS; COGNITION; GENETIC MARKERS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79955896410     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.9.1485923     Document Type: Review

References (73)

1. Woodcock J. Biomarkers: Physiological & Laboratory Markers of Drug Effect. http://www.cc.nih.gov/researchers/training/principles/ppt/woodcock-2006- 2007.ppt. Accessed April 4, 2010.
2. Atkinson, A.J. Jr., Colburn, W.A., DeGruttola, V.G. et al. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3): 89-95.
3. Stober, G., Ben-Shachar, D., Cardon, M. et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 2009, 10(2): 127-55.
4. Mayeux, R. Biomarkers: Potential uses and limitations. NeuroRx 2004, 1(2): 182-8.
5. Mikkelsen, J.D., Thomsen, M.S., Hansen, H.H., Lichota. J. Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discov Today 2010, 15(3-4): 137-41.
6. Gottesman, I.I., Gould, T.D. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 2003, 160(4): 636-45. (Pubitemid 41079594)
7. Raz, S., Raz, N. Structural brain abnormalities in the major psychoses: A quantitative review of the evidence from computerized imaging. Psychol Bull 1990, 108(1): 93-108.
8. Crow, T.J. Molecular pathology of schizophrenia: More than one disease process? Br Med J 1980, 280 (6207): 66-8.
9. Lawrie, S.M., Abukmeil, S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998, 172: 110-20. (Pubitemid 28097708)
10. Wright, I.C., Rabe-Hesketh, S., Woodruff, P.W., David, A.S., Murray, R.M., Bullmore, E.T. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000, 157(1): 16-25. (Pubitemid 30027416)
11. Shenton, M.E., Dickey, C.C., Frumin, M., McCarley, R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49(1-2): 1-52.
12. Baiano, M., David, A., Versace, A., Churchill, R., Balestrieri, M., Brambilla, P. Anterior cingulate volumes in schizophrenia: A systematic review and a meta-analysis of MRI studies. Schizophr Res 2007, 93(1-3): 1-12 (Pubitemid 46817932)
13. Konick, L.C., Friedman, L. Meta-analysis of thalamic size in schizophrenia. Biol Psychiatry 2001, 49(1): 28-38.
14. Milev, P., Ho, B.C., Arndt, S. et al. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: A prospective longitudinal study with 5-year follow-up. Biol Psychiatry 2003, 54(6): 608-15. (Pubitemid 41115097)
15. Steen, R.G., Mull, C., McClure, R., Hamer, R.M., Lieberman, J.A. Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006, 188: 510-8. (Pubitemid 43844097)
16. Kubicki, M., McCarley, R.W., Shenton, M.E. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 2005, 18(2): 121-34. (Pubitemid 40824443)
17. DeLisi. L.E. The concept of progressive brain change in schizophrenia: Implications for understanding schizophrenia. Schizophr Bull 2008, 34(2): 312-21. (Pubitemid 351323343)
18. Boos, H.B., Aleman, A., Cahn, W., Hulshoff, P.H., Kahn. R.S. Brain volumes in relatives of patients with schizophrenia: A meta-analysis. Arch Gen Psychiatry 2007, 64(3): 297-304. (Pubitemid 46376781)
19. Strasser, H.C., Lilyestrom, J., Ashby, E.R. et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: A pilot study. Biol Psychiatry 2005, 57(6): 633-9. (Pubitemid 40416707)
20. Moncrieff, J., Leo, J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010, 40(9): 1409-22.
21. Green, M.F., Kern, R.S., Braff, D.L., Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 2000, 26(1): 119-36.
22. Gur, R.E., Calkins, M.E., Gur, R.C., Horan, W.P., Nuechterlein, K.H., Seidman, L.J., Stone, W.S. The consortium on the genetics of schizophrenia: Neurocognitive endophenotypes. Schizophr Bull 2007, 33(1): 49-68.
23. Snitz, B.E., Macdonald, A.W. 3rd, Carter, C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: A meta-analytic review of putative endophenotypes. Schizophr Bull 2006, 32(1): 179-94. (Pubitemid 43063833)
24. Mesholam-Gately, R.I., Giuliano, A.J., Goff, K.P., Faraone, S.V., Seidman, L.J. Neurocognitlon in first-episode schizophrenia: A meta-analytic review. Neuropsychology 2009, 23(3): 315-36.
25. Minzenberg, M.J., Laird, A.R., Thelen, S., Carter, C.S., Glahn, D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psych 2009, 66(8): 811-22.
26. Hill, K., Mann, L., Laws, K.R., Stephenson, C.M., Nimmo-Smith, I., McKenna, P.J. Hypofrontality in schizophrenia: A meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004,110(4): 243-56. (Pubitemid 39278982)
27. Ragland, J.D., Gur, R.C., Valdez, J. et al. Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia. Am J Psychiatry 2004, 161(6): 1004-15.
28. Preston, A.R., Shohamy, D., Tamminga, C.A., Wagner, A.D. Hippocampal function, declarative memory, and schizophrenia: Anatomic and functional neuroimaging considerations. Curr Neurol Neurosci Rep 2005, 5(4): 249-56. (Pubitemid 41149659)
29. Ragland, J.D., Yoon, J., Minzenberg, M.J., Carter, C.S. Neuroimaging of cognitive disability in schizophrenia: Search for a pathophysiological mechanism. Int Rev Psychiatry 2007, 19(4): 417-27.
30. Zipursky, R.B., Meyer, J.H., Verhoeff, N.P. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 2007, 52(3): 146-57.
31. Kegeles, L.S., Abi-Dargham, A., Frankle, W.G. et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010, 67(3):231-9.
32. Keshavan, M.S., Tandon, R., Boutros, N.N., Nasrallah, H.A. Schizophrenia, "just the facts": What we know in 2008 Part 3: Neurobiology. Schizophr Res 2008, 106(2-3): 89-107.
33. McGuire, P., Howes, O.D., Stone, J., Fusar-Poli, P. Functional neuroimaging in schizophrenia: Diagnosis and drug discovery. Trends Pharmacol Sci 2008, 29(2): 91-8.
34. Abbott, C., Bustillo, J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 2006, 19(2): 135-9. (Pubitemid 44406123)
35. Smesny, S., Rosburg, T., Nenadic, I. et al. Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage 2007, 35(2): 729-37. (Pubitemid 46400550)
36. Turetsky, B.I., Calkins, M.E., Light, G.A., Olincy, A., Radant, A.D., Swerdlow, N.R. Neurophyslological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull 2007, 33(1): 69-94. (Pubitemid 46026260)
37. Freedman, R., Adler, L.E., Gerhardt, G.A. et al. Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull 1987, 13(4): 669-78. (Pubitemid 18037660)
38. Waldo, M., Adler, L.E., Leonard, S. et al. Familial transmission of risk factors in the first-degree relatives of schizophrenic people. Biol Psychiatry 2000, 47(3): 231-9. (Pubitemid 30077399)
39. Patterson, J.V., Hetrick, W.P., Boutros, N.N. et al. P50 sensory gating ratios in schizophrenics and controls: A review and data analysis. Psychiatry Res 2008, 158(2): 226-47.
40. Bramon, E., Rabe-Hesketh, S., Sham, P., Murray, R., Frangou, S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004, 70(2): 315-29. (Pubitemid 39141109)
41. Bramon, E., McDonald, C., Croft, R.J. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 2005, 27(4): 960-8. (Pubitemid 41319709)
42. Javitt, D.C., Spencer, K.M., Thaker, G.K., Winterer, G., Hajós, M. Neurophyslological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008, 7(1): 68-83.
43. Braff, D.L., Light, G.A. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci 2005, 7(2): 125-35. (Pubitemid 40961532)
44. Cadenhead, K.S., Light, G.A., Geyer, M.A., McDowell, J.E., Braff, D.L. Neurobiological measures of schizotypal personality disorder: Defining an inhibitory endophenotype? Am J Psychiatry 2002, 159(5): 869-71. (Pubitemid 34465067)
45. Umbricht, D., Krljes, S. Mismatch negativity in schizophrenia: A meta-analysis. Schizophr Res 2005, 76(1): 1-23. (Pubitemid 40824557)
46. Hall, M.H., Schulze, K., Bramon, E., Murray, R.M., Sham, P., Rijsdijk, F. Genetic overlap between P300, P50, and duration mismatch negativity. Am J Med Genet B Neuropsychiatr Genet 2006, 141B(4): 336-43. (Pubitemid 43872884)
47. Umbricht, D., Koller, R.,Schmid, L., Skrabo, A., Grübel, C.,Huber, T., Stassen, H. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 2003, 53(12): 1120-31.
48. Levy, D.L., Mendell, N.R., Holzman, P.S. The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: Empirical findings and interpretative considerations. World Psychiatry 2004, 3(1): 32-40.
49. Sullivan, P.F. The genetics of schizophrenia. PLos Med 2005, 2(7): e212.
50. Wray, N.R., Visscher, P.M. Narrowing the boundaries of the genetic architecture of schizophrenia. Schizophr Bull 2010, 36(1): 14-23.
51. St. Clair, D. Copy number variation and schizophrenia. Schizophr Bull 2009, 35(1): 9-12.
52. Chubb, J.E., Bradshaw, N.J., Soares, D.C., Porteous, D.J., Millar, J.K. The DISC locus in psychiatric illness. Mol Psychiatry 2008, 13(1): 36-64.
53. Talkowski, M.E., Chowdari, K., Lewis, D.A., Nimgaonkar, V.L. Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence. Schizophr Bull 2006, 32(2): 203-8
54. Buckholtz, J.W., Meyer-Lindenberg, A., Honea, R.A. et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 2007, 27: 1584-93.
55. Straub, R.E., Jiang, Y., MacLean, C.J. et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002, 71(2): 337-48. (Pubitemid 34800250)
56. Schwab, S.G., Wildenauer, D.B. Update on key previously proposed candidate genes for schizophrenia. Curr Opin Psychiatry 2009, 22(2): 147-53.
57. Mead, C.L., Kuzyk, M.A., Moradian, A., Wilson, G.M., Holt, R.A., Morin, G.B. Cytosolic protein interactions of the schizophrenia susceptibility gene dysbindin. J Neurochem 2010, 113(6): 1491-503.
58. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71(4): 877-92 (Pubitemid 135750519)
59. Harrison, P.J., Law, A.J. Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology. Biol Psychiatry 2006, 60(2): 132-40.
60. Munafò, M.R., Attwood, A.S., Flint, J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008, 34(1): 9-12.
61. Martineau, M., Baux, G., Mothet, J.P. D-serine signaling in the brain: Friend and foe. Trends Neurosci 2006, 29: 481-91. (Pubitemid 44118443)
62. Craddock, N., Forty, L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006, 14: 660-8. (Pubitemid 43797263)
63. Gothelf, D., Schaer, M., Eliez, S. Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome. Dev Disabil Res Rev 2008, 14(1): 59-68. (Pubitemid 351716524)
64. Willis, A., Bender, H.U., Steel, G., Valle, D. PRODH variants and risk for schizophrenia. Amino Acids 2008, 35(4): 673-9.
65. Gejman, P.V., Sanders, A.R., Duan, J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am 2010, 33(1): 35-66.
66. Peedicayil, J. The role of epigenetlcs in altered gene expression involved in GABAergic transmission in the cerebellum of schizophrenia patients. Am J Psychiatry 2009, 166(4): 493.
67. Krebs, M.O., Bellon, A., Mainguy, G., Jay, T.M., Frieling, H. One-carbon metabolism and schizophrenia: Current challenges and future directions. Trends Mol Med 2009, 15(12): 562-70.
68. Fatemi, S.H. Reelin glycoprotein: Structure, biology and roles in health and disease. Mol Psychiatry 2005, 10(3): 251-7. (Pubitemid 40432679)
69. Grayson, D.R., Jia, X., Chen, Y. et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005, 102(26): 9341-6. (Pubitemid 40923565)
70. Suzuki, K., Nakamura, K., Iwata, Y. et al. Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr Res 2008, 98(1-3): 148-56. (Pubitemid 350235901)
71. Kim, Y.K., Kim, L., Lee, M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000, 44(3): 165-75.
72. Huang, J.T., Leweke, F.M., Oxley, D. et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006, 3(11): e428.
73. Banati, R., Hickie, I.B. Therapeutic signposts: Using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust 2009, 190(4, Suppl.): S26-32.